A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, fo ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Other approved drugs like Kesimpta (multiple sclerosis) and Leqvio (heart and cholesterol disease) are also contributing to ...

Novartis will give Lindy $20 million up front and potentially up to $934 million in milestone and royalty payments. Lindy’s technology, which it calls “microglassification,” makes biologic ...

NVS), but they think it will take until next year for Novartis’ upcoming drug approvals and launches to attract investor attention. Jim Cramer points out that while the downgrade reflects a ...

Leerink’s Risinger also noted how, even if tolebrutinib is approved, insurers may limit access in nrSPMS and prioritize off-label use of other MS drugs since it couldn’t outperform Aubagio. Further ...